Main Article Content

Shafi Muhammad khuhawar
Jagdesh Kumar
Khalil Ahmed Sanghro
Bashir Ahmed Chandio
Murk kukreja


Empyema Thoracis, antibiogram, antibiotics


Background; empyema thoracis is defined as an accumulation of pus within the pleural space and has been associated with a high death rate. The aim of the study was to find out the Culture and sensitivity patterns of the causative organisms isolated from the patient of Empyema Thoracis.

Material and method; the current descriptive cross-sectional study was carried out at the department of Pulmonology, GMMMC hospital Sukkur from January 2023 to November 2023 after taking approval from the ethical committee of the institute.  A total of 224 individuals of both genders age ranged from 20-60 years were enrolled in this study. All the individuals were evaluated for empyema thoracis. Historical data on demographics was documented. Every patient had a tube tharacostomy pleural drainage surgery, and empiric antibiotics were started to treat the pleural infection. For antibiogram antibiotics used were Amoxicillin, Gentamicin, Amikacin,, Cefotaxime, Ciprofloxacin, Co-amoxiclav, and Moxifloxacin. Based on results, they were classified as sensitive or resistant. All the data was analyzed through SPSS.

Results; A total of 224 were examined. Out of the total patients 33.9% had culture positive results. Of the individuals who tested positive for culture, 48 were men and 26 were women. Culture sensitivity results evaluated that Out of the 224 individuals, 61 (27.2. %) showed sensitivity to cefotaxime, ceftriaxone, ciprofloxacin, and moxifloxacin; 58 (25.8%) to gentamycin; 57 (25.4%) to cephradine and Co-amoxiclav; and 48 (21.4%) to amoxicillin. 

Conclusion: From the current study it was concluded that Less than one-third of individuals with empyema thoracis have positive empyema fluid cultures and most of the organisms are sensitive to the majority of routinely used antibiotics.

Abstract 97 | PDF Downloads 31


1. Fraser RS, Muller NL, Colman N, Pare PD. Pleural Effusion. In. Fraser and Pare’s Diagnosis of Diseases of the Chest, 4th ed., Volume IV Philadelphia, W.B. Saunders Company; 1999:27412747.
2. Light RW. Pleural diseases. 3rd edn. Baltimore, Williams and Wilkins; 1995. In Hamm H, Light RW. Parapneumonic effusion and empyema. Eur Respir J. 2003;10:1150-6
3. Chen KY, Hsueh P, Liaw Y, Yang P, Luh K. A 10-year experience with bacteriology of acute thoracic empyema. Chest. 2000; 117:1685-9
4. Mancini P, Mazzei L, Zarzana A, Biagioli D, Sposato B, Croce GF. Post-tuberculosis chronic empyema of the “forty years after". Eur Rev Med Pharmacol Sci. 2000;2:25-9
5. Ahmed RA, Marrie TJ, Huang JQ. Thoracic empyema in patients with community-acquired Pneumonia. Am J Med. 2006:119:877-83.
6. Finley C, Clifton J, Fitzgerald JM. Empyema: an increasing concern in Canada. Can Respir J. 2008;15:85-9
7. Brims FJH, Lansley SM, Waterer GW, Lee YCG. Empyema thoracic: new insights into an old disease. Eur Respir Rev. 2010; 19:117:220-8
8. Atif M, Naseem M, Sarwar S, Mukhtar S, Malik I,Hassan MRu, Iqbal MN and Ahmad N (2021) Spectrum of Microorganisms, Antibiotic Resistance Pattern, and Treatment Outcomes among Patients With Empyema Thoracis: A Descriptive Cross-Sectional Study From the Bahawal Victoria Hospital Bahawalpur, Punjab, Pakistan. Front. Med. 8:665963.
9. Pulle MV, Asaf BB, Kumar A, Puri HV, Vijay C, Bishnoi S. Microbiological profile of tubercular and nontubercular empyemas and its impact on clinical outcomes: a retrospective analysis of 285 consecutively operated cases. Lung India. (2020) 37:389–93.
10. Ayala A, Uribe J, Mitchell M, Majid A, Parikh M,Chee A. Institutional empyema trend analysis: an increasing concern. A59 clinical diagnosis, prediction and outcomes of lung infections. Am Thorac Soc. (2020) A2153-A.
11. Atif M, Zia R, Malik I, Ahmad N, Sarwar S.Treatment outcomes, antibiotic use and its resistance pattern among neonatal sepsis patients attending Bahawal Victoria Hospital, Pakistan. PLoS ONE. (2021) 16:e0244866.
12. Conti P, Younes A. Coronavirus COV-19/SARSCoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents. (2020) 34: 339–43.
13. Tareen S, Aman R, Hussain S, Masoom A, Zaman M, Massod MK. Bacteriology of acute thoracic empyema in a tertiary care hospital. Int J Pathol 2007;5:72-6
14. Afzal M. Antibiotic resistance pattern of escherichia coli and klebsiella species in pakistan: a brief overview. J Microb Biochem Technol. (2017) 9:277–9
15. Atif M, Ihsan B, Malik I, Ahmad N, Saleem S, Sehar A, et al. Antibiotic stewardship program in Pakistan: a multicenter qualitative study exploring doctors' knowledge, perception and practices. BMC Infect Dis. (2021) 21:374.
16. Malik I, Atif M. Global menace of superbugs: time to consider a “Pharmacist led One Health Approach” to counteract the crisis. Res Social Adm Pharm. (2020) 16:848–9.
17. Rahman NM, Davies RJO. Effusions from infections: parapneumonic effusion and empyema. In:Light RW, Lee YCG editors. Textbook of pleural disease. 2nd ed. London: Hodder Arnold, 2008; p.341–66.
18. Melloni G, Carretta A, Ciriaco P, Negri G, Voci C, Augello G, et al. Decortication for chronic parapneumonic empyema: results of a prospective study. World J Surg. 2004; 28:488–93
19. Afzal M. Antibiotic resistance pattern of escherichia coli and klebsiella species in pakistan: a brief overview. J Microb Biochem Technol. (2017) 9:277–9.

Most read articles by the same author(s)